{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:43:20Z","timestamp":1780490600910,"version":"3.54.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, USA"},{"name":"Intramural Research Program of the National Center for Advancing Translational Sciences, National Institutes of Health, USA"},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP18fk0210020h0002"],"award-info":[{"award-number":["JP18fk0210020h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006729","name":"Kansas University | School of Medicine, University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006729","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Molecular Libraries Initiative funding to the University of Kansas Specialized Chemistry Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"DOI":"10.1038\/s41564-020-0781-2","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T16:04:06Z","timestamp":1598889846000},"page":"1532-1541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4520-5849","authenticated-orcid":false,"given":"Christopher D.","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Talley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Rolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Q.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsutaka","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Teraoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Bum","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishanth","family":"Chalasani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parker H.","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres E.","family":"Dulcey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Southall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Marugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7173-6352","authenticated-orcid":false,"given":"Kevin J.","family":"Frankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3828-702X","authenticated-orcid":false,"given":"Tsanyang Jake","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"781_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach, S. et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol. Hepatol. 2, 161\u2013176 (2017).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"781_CR2","doi-asserted-by":"crossref","first-page":"e928","DOI":"10.1016\/j.ijid.2010.03.019","volume":"14","author":"S Jafari","year":"2010","unstructured":"Jafari, S., Copes, R., Baharlou, S., Etminan, M. & Buxton, J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int. J. Infect. Dis. 14, e928\u2013e940 (2010).","journal-title":"Int. J. Infect. Dis."},{"key":"781_CR3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/hep.21902","volume":"47","author":"JT Blackard","year":"2008","unstructured":"Blackard, J. T., Shata, M. T., Shire, N. J. & Sherman, K. E. Acute hepatitis C virus infection: a chronic problem. Hepatology 47, 321\u2013331 (2008).","journal-title":"Hepatology"},{"key":"781_CR4","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMra1213651","volume":"368","author":"TJ Liang","year":"2013","unstructured":"Liang, T. J. & Ghany, M. G. Current and future therapies for hepatitis C virus infection. N. Engl. J. Med. 368, 1907\u20131917 (2013).","journal-title":"N. Engl. J. Med."},{"key":"781_CR5","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMe1403619","volume":"370","author":"TJ Liang","year":"2014","unstructured":"Liang, T. J. & Ghany, M. G. Therapy of hepatitis C\u2014back to the future. N. Engl. J. Med 370, 2043\u20132047 (2014).","journal-title":"N. Engl. J. Med"},{"key":"781_CR6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2018.10.048","volume":"156","author":"JW Ward","year":"2019","unstructured":"Ward, J. W. & Hinman, A. R. What is needed to eliminate hepatitis B virus and hepatitis C virus as global health threats. Gastroenterology 156, 297\u2013310 (2019).","journal-title":"Gastroenterology"},{"key":"781_CR7","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem, S. et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N. Engl. J. Med 370, 1993\u20132001 (2014).","journal-title":"N. Engl. J. Med"},{"key":"781_CR8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/hep.30225","volume":"69","author":"S Fourati","year":"2019","unstructured":"Fourati, S. et al. Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. Hepatology 69, 513\u2013523 (2019).","journal-title":"Hepatology"},{"key":"781_CR9","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jhep.2019.07.025","volume":"71","author":"K Childs","year":"2019","unstructured":"Childs, K. et al. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: implications for global elimination of hepatitis C. J. Hepatol. 71, 1099\u20131105 (2019).","journal-title":"J. Hepatol."},{"key":"781_CR10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","volume":"4","author":"L Wei","year":"2019","unstructured":"Wei, L. et al. Sofosbuvir\u2013velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol. Hepatol. 4, 127\u2013134 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"781_CR11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1124\/dmd.117.079038","volume":"46","author":"KL Garrison","year":"2018","unstructured":"Garrison, K. L., German, P., Mogalian, E. & Mathias, A. The drug\u2013drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab. Dispos. 46, 1212\u20131225 (2018).","journal-title":"Drug Metab. Dispos."},{"key":"781_CR12","first-page":"996","volume":"318","author":"R Voelker","year":"2017","unstructured":"Voelker, R. The 8-week cure for hepatitis C. JAMA 318, 996 (2017).","journal-title":"JAMA"},{"key":"781_CR13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"J-M Pawlotsky","year":"2016","unstructured":"Pawlotsky, J.-M. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151, 70\u201386 (2016).","journal-title":"Gastroenterology"},{"key":"781_CR14","unstructured":"Kurosaki, M. et al. Nation-wide real world study of NS5A resistance\u2010associated substitutions in patients who failed prior daclatasvir plus asunaprevir: identification of specific pattern that impacts re\u2010treatment outcome by ledipasvir\/sofosbuvir. Hepatology 68, abstr. 200 (2018)."},{"key":"781_CR15","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jhep.2017.09.008","volume":"68","author":"VC Di Maio","year":"2018","unstructured":"Di Maio, V. C. et al. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens? J. Hepatol. 68, 597\u2013600 (2018).","journal-title":"J. Hepatol."},{"key":"781_CR16","unstructured":"Howe, A. et al. A real world resistance profile of virologic failures collected from an international collaboration (SHARED). Hepatology 68, abstr. 204 (2018)."},{"key":"781_CR17","doi-asserted-by":"crossref","first-page":"e12997","DOI":"10.1111\/tid.12997","volume":"21","author":"EM Teegen","year":"2019","unstructured":"Teegen, E. M., Maurer, M. M., Globke, B., Pratschke, J. & Eurich, D. Liver transplantation for hepatitis-B-associated liver disease\u2014three decades of experience. Transpl. Infect. Dis. 21, e12997 (2019).","journal-title":"Transpl. Infect. Dis."},{"key":"781_CR18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1128\/AAC.02094-13","volume":"58","author":"Z Hu","year":"2014","unstructured":"Hu, Z. et al. Novel cell-based hepatitis C virus infection assay for quantitative high-throughput screening of anti-hepatitis C virus compounds. Antimicrob. Agents Chemother. 58, 995\u20131004 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"781_CR19","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1021\/acs.jmedchem.7b00561","volume":"60","author":"S He","year":"2017","unstructured":"He, S. et al. Development of an aryloxazole class of hepatitis C virus inhibitors targeting the entry stage of the viral replication cycle. J. Med. Chem. 60, 6364\u20136383 (2017).","journal-title":"J. Med. Chem."},{"key":"781_CR20","first-page":"282ra249","volume":"7","author":"S He","year":"2015","unstructured":"He, S. et al. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci. Transl. Med. 7, 282ra249 (2015).","journal-title":"Sci. Transl. Med."},{"key":"781_CR21","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/JVI.80.4.1734-1741.2006","volume":"80","author":"DM Tscherne","year":"2006","unstructured":"Tscherne, D. M. et al. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 80, 1734\u20131741 (2006).","journal-title":"J. Virol."},{"key":"781_CR22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/1743-422X-8-163","volume":"8","author":"UA Ashfaq","year":"2011","unstructured":"Ashfaq, U. A., Javed, T., Rehman, S., Nawaz, Z. & Riazuddin, S. Lysosomotropic agents as HCV entry inhibitors. Virol. J. 8, 163 (2011).","journal-title":"Virol. J."},{"key":"781_CR23","doi-asserted-by":"crossref","first-page":"30361","DOI":"10.1074\/jbc.M111.263350","volume":"286","author":"NR Sharma","year":"2011","unstructured":"Sharma, N. R. et al. Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J. Biol. Chem. 286, 30361\u201330376 (2011).","journal-title":"J. Biol. Chem."},{"key":"781_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1128\/AAC.02083-13","volume":"58","author":"CO Bush","year":"2014","unstructured":"Bush, C. O. et al. A small-molecule inhibitor of hepatitis C virus infectivity. Antimicrob. Agents Chemother. 58, 386\u2013396 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"781_CR25","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1093\/jac\/dkw336","volume":"71","author":"N Zhou","year":"2016","unstructured":"Zhou, N. et al. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J. Antimicrob. Chemother. 71, 3495\u20133505 (2016).","journal-title":"J. Antimicrob. Chemother."},{"key":"781_CR26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/hep.22673","volume":"49","author":"JM Gottwein","year":"2009","unstructured":"Gottwein, J. M. et al. Development and characterization of hepatitis C virus genotype 1\u20137 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49, 364\u2013377 (2009).","journal-title":"Hepatology"},{"key":"781_CR27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3851\/IMP3044","volume":"21","author":"B Lin","year":"2016","unstructured":"Lin, B., He, S., Yim, H. J., Liang, T. J. & Hu, Z. Evaluation of antiviral drug synergy in an infectious HCV system. Antivir. Ther. 21, 595\u2013603 (2016).","journal-title":"Antivir. Ther."},{"key":"781_CR28","doi-asserted-by":"crossref","unstructured":"Bijnsdorp, I. V., Giovannetti, E. & Peters, G. J. in Cancer Cell Culture: Methods and Protocols (ed. Cree, I. A.) 421\u2013434 (Springer Science+Business Media, 2011).","DOI":"10.1007\/978-1-61779-080-5_34"},{"key":"781_CR29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","volume":"14","author":"MN Prichard","year":"1990","unstructured":"Prichard, M. N. & Shipman, C.Jr. A three-dimensional model to analyze drug-drug interactions. Antivir. Res. 14, 181\u2013205 (1990).","journal-title":"Antivir. Res."},{"key":"781_CR30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2018.03.007","volume":"69","author":"M Puoti","year":"2018","unstructured":"Puoti, M. et al. High SVR12 with 8-week and 12-week glecaprevir\/pibrentasvir therapy: an integrated analysis of HCV genotype 1\u20136 patients without cirrhosis. J. Hepatol. 69, 293\u2013300 (2018).","journal-title":"J. Hepatol."},{"key":"781_CR31","first-page":"e01620-","volume":"62","author":"TI Ng","year":"2017","unstructured":"Ng, T. I. et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3\/4A protease inhibitor glecaprevir. Antimicrob. Agents Chemother. 62, e01620-17 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"781_CR32","first-page":"e02558-","volume":"61","author":"TI Ng","year":"2017","unstructured":"Ng, T. I. et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob. Agents Chemother. 61, e02558-16 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"781_CR33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00535-018-1520-9","volume":"54","author":"M Osawa","year":"2019","unstructured":"Osawa, M. et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J. Gastroenterol. 54, 291\u2013296 (2019).","journal-title":"J. Gastroenterol."},{"key":"781_CR34","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1099\/jgv.0.001268","volume":"100","author":"M Osawa","year":"2019","unstructured":"Osawa, M. et al. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. J. Gen. Virol. 100, 1123\u20131131 (2019).","journal-title":"J. Gen. Virol."},{"key":"781_CR35","first-page":"e01249-","volume":"62","author":"P Krishnan","year":"2018","unstructured":"Krishnan, P. et al. Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials. Antimicrob. Agents Chemother. 62, e01249-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"781_CR36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1423-0127-16-89","volume":"16","author":"HF Li","year":"2009","unstructured":"Li, H. F., Huang, C.-H., Ai, L.-S., Chuang, C.-K. & Chen, S. S. L. Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry. J. Biomed. Sci. 16, 89 (2009).","journal-title":"J. Biomed. Sci."},{"key":"781_CR37","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3389\/fimmu.2018.01411","volume":"9","author":"Y Tong","year":"2018","unstructured":"Tong, Y., Lavillette, D., Li, Q. & Zhong, J. Role of hepatitis C virus envelope glycoprotein E1 in virus entry and assembly. Front. Immunol. 9, 1411 (2018).","journal-title":"Front. Immunol."},{"key":"781_CR38","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.chembiol.2020.04.006","volume":"27","author":"Z Hu","year":"2020","unstructured":"Hu, Z. et al. Chlorcyclizine inhibits viral fusion of hepatitis C virus entry by directly targeting HCV envelope glycoprotein 1. Cell Chem. Biol. 27, 780\u2013792 (2020).","journal-title":"Cell Chem. Biol."},{"key":"781_CR39","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1128\/JVI.74.8.3623-3633.2000","volume":"74","author":"L Cocquerel","year":"2000","unstructured":"Cocquerel, L., Wychowski, C., Minner, F., Penin, F. & Dubuisson, J. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J. Virol. 74, 3623\u20133633 (2000).","journal-title":"J. Virol."},{"key":"781_CR40","doi-asserted-by":"crossref","first-page":"e02309-","DOI":"10.1128\/JVI.02309-16","volume":"91","author":"H Freedman","year":"2017","unstructured":"Freedman, H. et al. Computational prediction of the heterodimeric and higher-order structure of gpE1\/gpE2 envelope glycoproteins encoded by hepatitis C virus. J. Virol. 91, e02309-16 (2017).","journal-title":"J. Virol."},{"key":"781_CR41","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/prot.10611","volume":"54","author":"AW Partridge","year":"2004","unstructured":"Partridge, A. W., Therien, A. G. & Deber, C. M. Missense mutations in transmembrane domains of proteins: phenotypic propensity of polar residues for human disease. Proteins 54, 648\u2013656 (2004).","journal-title":"Proteins"},{"key":"781_CR42","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1126\/science.1243876","volume":"342","author":"L Kong","year":"2013","unstructured":"Kong, L. et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science 342, 1090\u20131094 (2013).","journal-title":"Science"},{"key":"781_CR43","doi-asserted-by":"crossref","first-page":"12776","DOI":"10.1128\/JVI.00901-13","volume":"87","author":"SBN Serre","year":"2013","unstructured":"Serre, S. B. N., Krarup, H. B., Bukh, J. & Gottwein, J. M. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance. J. Virol. 87, 12776\u201312793 (2013).","journal-title":"J. Virol."},{"key":"781_CR44","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2016.04.016","volume":"65","author":"P Bogomolov","year":"2016","unstructured":"Bogomolov, P. et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib\/IIa study. J. Hepatol. 65, 490\u2013498 (2016).","journal-title":"J. Hepatol."},{"key":"781_CR45","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S2468-1253(19)30240-7","volume":"4","author":"ED Bethea","year":"2019","unstructured":"Bethea, E. D. et al. Pre-emptive pangenotypic direct acting antiviral therapy in donor HCV-positive to recipient HCV-negative heart transplantation: an open-label study. Lancet Gastroenterol. Hepatol. 4, 771\u2013780 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"781_CR46","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","volume":"380","author":"AE Woolley","year":"2019","unstructured":"Woolley, A. E. et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N. Engl. J. Med. 380, 1606\u20131617 (2019).","journal-title":"N. Engl. J. Med."},{"key":"781_CR47","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1093\/infdis\/jiy039","volume":"217","author":"A Rolt","year":"2018","unstructured":"Rolt, A. et al. Preclinical pharmacological development of chlorcyclizine derivatives for the treatment of hepatitis C virus infection. J. Infect. Dis. 217, 1761\u20131769 (2018).","journal-title":"J. Infect. Dis."},{"key":"781_CR48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.28111","volume":"63","author":"PM Perin","year":"2016","unstructured":"Perin, P. M. et al. Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology 63, 49\u201362 (2016).","journal-title":"Hepatology"},{"key":"781_CR49","doi-asserted-by":"crossref","first-page":"8422","DOI":"10.1128\/JVI.00404-16","volume":"90","author":"T Vausselin","year":"2016","unstructured":"Vausselin, T. et al. Identification of a new benzimidazole derivative as an antiviral against hepatitis C virus. J. Virol. 90, 8422\u20138434 (2016).","journal-title":"J. Virol."},{"key":"781_CR50","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.virol.2015.03.043","volume":"479\u2013480","author":"SC Harrison","year":"2015","unstructured":"Harrison, S. C. Viral membrane fusion. Virology 479\u2013480, 498\u2013507 (2015).","journal-title":"Virology"},{"key":"781_CR51","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/pmic.200300780","volume":"4","author":"J-N Rybak","year":"2004","unstructured":"Rybak, J.-N., Scheurer, S. B., Neri, D. & Elia, G. Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics 4, 2296\u20132299 (2004).","journal-title":"Proteomics"}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-0781-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-0781-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-0781-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T04:01:34Z","timestamp":1670299294000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-020-0781-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1038\/s41564-020-0781-2","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"9 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}